Recombinant protein expression in
Recombinant protein expression has revolutionized all aspects of the biological sciences. Most significantly, it has dramatically expanded the number of proteins that can be investigated both biochemically and structurally. Previously, protein production was the domain of experts, as purification from a natural source (i.e., plants, rabbits, bovine) was often difficult and time consuming. However, the availability of new commercial systems for recombinant protein expression, combined with advanced protein purification techniques, has made protein production prevalent throughout the biological and biomedical sciences. This has enabled the research community to study thousands of low abundance and novel proteins from a large variety of organisms. Notably, 31 recombinant proteins were approved for therapeutic use between 2003 and 2006, highlighting the importance of heterologous protein expression in biopharmaceutical research (Walsh,
In spite of the development of multiple nonbacterial recombinant expression systems over the last three decades (yeast, baculovirus, mammalian cell, cell free systems; see Table
Comparison of Recombinant Protein Expression Systems
|
|
Yeast |
Insect cells |
Mammalian cells |
Cell‐free |
Cell‐free |
|
|---|---|---|---|---|---|---|
|
Average time of cell division |
30 min |
90 min |
18 hr |
24 hr |
N/A |
N/A |
|
Cost of expression |
Low |
Low |
High |
High |
High |
High |
|
Expression level |
High |
Low‐High |
Low‐High |
Low‐Moderate |
Low‐High |
Low‐High |
|
Success rate (% soluble) |
40‐60 |
50‐70 |
50‐70 |
80‐95 |
Variable |
Variable |
|
Advantages |
Simple, low cost, rapid, robust, high yield, easy labeling for structural studies |
Simple, low cost |
Post‐translational modifications |
Natural protein configuration, post‐translational modifications |
High yield, fast, flexible, disulfide‐bonded and membrane proteins, easy labeling for structural studies |
Fast, flexible, disulfide‐bonded and membrane proteins, post‐translational modifications |
|
Disadvantages |
No post‐translational modifications, insoluble protein, production of disulfide‐bonded and membrane proteins is difficult |
Less post‐translational modifications, production of membrane proteins is difficult |
Slow, higher cost, production of membrane proteins is difficult |
Slow, high cost, lower yield |
High cost, less post‐translational modifications, efficient production requires highly‐specialized setup |
High cost, lower yield than |
Spirin,
Despite its many advantages and widespread use, there are also disadvantages to using
Considerable efforts have been made in recent years to maximize the efficient production of soluble recombinant proteins in bacteria. A remarkable number of novel reagents (new vectors, new host strains) and strategies (chaperone co‐expression, low temperature induction) have been developed that allow many of these disadvantages to be readily and successfully overcome. It is this topic, how to optimize soluble protein expression in
Schematic overview of the topics covered in this review, highlighting the multiple parameters (listed on the right) that can greatly impact the success of soluble expression.
Before initiating a protein expression project, it is essential to determine the definitive use of the recombinantly produced protein. Must the protein be soluble? Does the final product need to be active? Is the native protein conformation important? In some instances, such as antibody production, the production of soluble protein is not necessary, as the protein sequence, rather than the correct 3‐dimensional fold, is required for successful antibody production (Yan et al.,
Expression in
Flowchart of a general expression protocol used by the authors to express a broad range of targets, from phosphatases, to neuronal scaffolding proteins, to bacterial signaling proteins. The approximate time required to complete each segment of the protocol is listed to the left of the corresponding step.
The protocol outlined in Figure
This protocol is meant to serve as a starting point for designing an expression strategy in
Here, we discuss critical characteristics of the gene and/or protein sequence that influence its soluble expression in
One of the most common reasons that heterologous proteins fail to express in
Fortunately, the codon bias of
Both approaches effectively overcome codon bias. For example, codon optimization of the human β‐defensin 2 (hBD2) gene led to a nine‐fold enhancement in the expression level (Peng et al.,
The evolution of eukaryotes has been characterized by a significant increase in the size and complexity of proteins; e.g., the average protein length in
The starting and ending residues of the target domain can also greatly affect expression yield and solubility. For example, Klock et al. (
Once the protein target and corresponding construct(s) are determined, it must be subcloned into a vector that contains all DNA sequence elements that direct the transcription and translation of the target gene (Studier and Moffatt,
The origin of replication of a vector is the site where replication is initiated. It also determines copy number of the vector in the host. The copy number for common
Promoters are another element of the vector that can have a profound effect on the strength and duration of transcription and, in turn, protein yield. Synthesis of mRNA is initiated when RNA polymerase binds to a specific DNA sequence, the promoter, adjacent to the target gene. This sequence contains the transcription start site, as well as two hexanucleotide sequences approximately 10 and 35 bases upstream of the initiation site that direct the binding of essential elements of the polymerase machinery (Rosenberg and Court,
When selecting a promoter system, the nature of the protein target and its desired downstream use must be considered. If the protein target is a toxic protein (like a ribonuclease), one should consider using promoter systems that have extremely low basal expression, such as the
Promoter Systems used to Direct Recombinant Protein Expression in
|
|
Description |
Induction |
Advantages |
Disadvantages |
|---|---|---|---|---|
|
|
||||
|
T7 RNA polymerase |
T7 RNA polymerase gene under the control of L8‐UV5 |
IPTG |
High level of expression: accumulate up to 50% total cell protein Well characterized, used most often Titrate expression using Tuner strains |
Leaky expression: use pLysS strains for expression of proteins toxic to host |
|
|
Promoter is controlled by AraC regulator |
|
Tight regulation Titrate expression levels from low to high Low basal expression: suitable for production of proteins toxic to host |
Repressed expression state is not always zero, gene‐dependent |
|
|
−35 sequence from |
IPTG |
High level of expression: accumulate 15%‐30% of total cell protein |
Very leaky expression: not optimal for expression of proteins toxic to host Newer, more efficient systems are available |
|
|
Promoter from the major cold‐shock protein in |
Temperature downshift from 37°C (expression optimal between 10°C‐25°C) |
Efficient expression at low temperatures Can improve folding, lower inclusion body formation Advantageous for expression of aggregation‐prone and proteolytically‐sensitive proteins Induction is cost efficient |
Leaky expression: not optimal for expression of proteins toxic to host Translational efficiency slows at lower temperatures Not titratable |
|
|
||||
|
Phage promoter |
Phage promoter that is regulated by the temperature‐sensitive cI repressor |
Temperature shift from 30°C to 42°C |
Moderately high expression Induction is cost efficient |
High basal level of expression at temperatures below 30°C Induction cannot be performed at low temperatures |
|
|
Promoter for the gene of the periplasmic alkaline phosphatase |
Lower phosphate concentration in the growth medium |
Promotes secretion to the periplasm Inexpensive induction |
Phosphate limitation can have negative effects on metabolism of host cell Not titratable Limited media options |
|
|
Promoter for |
Nalidixic acid |
Tight regulation No growth media or temperature restrictions |
Not titratable |
|
|
Regulated by the tetR repressor |
Anhydrotetracycline |
Moderately high expression Low basal expression Independent of |
Not titratable |
See Elvin et al.,
See Kikuchi et al.,
See Shirakawa et al.,
See Delatorre et al.,
Once induced, most of the cellular machinery is devoted to the production of the recombinant protein, comprising up to 50% of the total cellular protein (Studier and Moffatt,
Fusion tags are proteins or peptides that are genetically fused to the target protein. They are useful because they can improve protein expression, promote folding, increase protein solubility, and facilitate downstream processes such as purification and detection. However, the “perfect” tag, i.e., one that can perform all of these tasks for every protein, still does not exist. Thus, it is often necessary to test multiple fusion tags to determine which tag results in the highest yields of soluble protein (Peti and Page,
Characteristics of Commonly used Fusion Tags
|
Tag |
Protein |
Amino acids |
Size (kDa) |
Source organism |
Purification aid |
Affinity matrix |
Comments |
|---|---|---|---|---|---|---|---|
|
|
|||||||
|
GST |
Glutathione |
243 |
28.1 |
|
Yes |
Glutathione agarose |
Forms dimer in solution |
|
MBP |
Maltose binding protein |
390 |
43.0 |
|
Yes |
Amylose resin |
Strong solubility‐enhancer |
|
DsbA |
Disulfide oxidoreductase |
228 |
25.4 |
|
No |
Aids periplasmic disulfide‐bond formation |
|
|
NusA |
N‐utilizing substance A protein |
535 |
59.3 |
|
No |
Strong solubility‐enhancer |
|
|
Trx |
Thioredoxin |
135 |
14.7 |
|
No |
Aids cytosolic disulfide‐bond formation |
|
|
Z‐domain |
Protein A IgG ZZ repeat domain |
91 |
10.6 |
|
Yes |
Protein A‐sepharose |
|
|
GB1 |
Protein G β1 domain |
85 |
9.7 |
|
Yes |
IgG‐resins |
Used often with proteins for NMR |
|
SUMO |
Small ubiquitin‐like modifier |
99 |
11.1 |
|
No |
||
|
SET |
Solubility‐enhancing tags |
<40 |
T7 phage gene 10B; synthetic |
No |
Small, highly acidic peptide tags that limit protein aggregation |
||
|
HaloTag‐7 |
Catalytically‐inactive derivative of DhaA |
296 |
34.0 |
|
Yes |
HaloLink resin |
Strong solubility‐enhancer |
|
|
|||||||
|
His6 |
Hexahistadine |
6 |
0.8 |
Synthetic |
Yes |
Immobilized metal resin |
Often combined with solubility‐enhancing tags |
|
Intein |
Protein splicing element |
128‐1650 |
Variable |
Yes |
Chitin resin |
Remove from resin by induced self‐cleavage |
|
See Nilsson et al.,
See Bao et al.,
See Ohana et al.,
See Chong et al.,
Trx is also the fusion tag of choice if expressing a protein that contains disulfide bonds. To overcome the highly reductive environment of the bacterial cytosol, new bacterial strains, which contain mutations in two proteins that play key roles in maintaining the reducing environment of the cytosol, thioredoxin reductase (
MBP is most commonly used as an N‐terminal tag. However, unlike Trx, which is only effective as an N‐terminal fusion tag, MBP has been shown to effectively enhance protein solubility as both an N‐ and a C‐terminal fusion tag (Dyson et al.,
While the effective increase in solubility and affinity properties are highly favorable, MBP also has less desirable traits, which is why it is not the “perfect” tag. The protein is very large (42 kD) and its presence can interfere with biological activity of the recombinant protein if not removed. Moreover, MBP enhances solubility so strongly that it can even solubilize unfolded/misfolded proteins. In these cases, the target proteins often precipitate after enzymatic cleavage of MBP, resulting in wasted time and resources (Lee et al.,
Several proteases are widely used for fusion tag removal (see Table
Commonly used Proteases to Remove Fusion Tags from Recombinant Proteins
|
Protease |
Description |
Cleavage site |
Protease inhibitors |
Activity |
Comments |
|---|---|---|---|---|---|
|
TEV |
Catalytic domain of the Nuclear Inclusion a (NIa) protein, a cysteine protease, found in the tobacco etch virus (TEV) |
EXXYXQ‐(G/S) Most common: ENLYFQ‐X |
PMSF, AEBSF, TLCK, pepstatin A, bestatin, E‐64, zinc (>5 mM), EDTA (1 mM), reagents that react with cysteine; various detergents |
pH: 4‐9 Temperature: 4°C‐37°C (max. at 34°C) Can accommodate most buffers |
Sequence specificity more stringent than factor Xa, thrombin, and enterokinase Can be produced in |
|
3C |
Recombinant form of the 3C protease from human rhinovirus type 14 |
EVLFQ‐GP |
PMSF, TLCK, leupeptin, zinc (100 mM), urea (1 M), guanidine (1 M) |
pH: 3‐10 Temperature: 4°C‐37°C (max. at 4°C) Test activity in buffer of choice |
High sequence specificity Can be produced in |
|
Xa |
Factor Xa is a serine protease that converts prothrombin to thrombin |
I(E/N)GR‐ Will not cleave at site followed by P or R |
PMSF, AEBSF, DFP, aprotinin, antithrombin III, antipain, α1‐antitypsin, chymostatin, hirudin, leupeptin, urea (100 mM), guanidine (10 mM), NaCl (100 mM), imidazole (100 mM) |
pH: 6.5‐9 Temperature: 4°C‐37°C Activity is highly reduced in phosphate buffers compared to Tris or HEPES, CaCl2 should be included in cleavage reaction |
Nonspecific proteolysis may occur at secondary sites Cleavage usually performed near physiological conditions |
|
Thr |
Thrombin is a serine protease that converts fibrinogen into fibrin |
LVPR‐GS |
PMSF, AEBSF, aprotinin, antithrombin III, antipain, α1‐antitypsin, chymostatin, hirudin, leupeptin, reducing agents |
pH: 5‐10 Temperature: 4°C‐37°C (max. at 37°C) Can accommodate most buffers |
Nonspecific proteolysis may occur at secondary sites Cleavage usually performed near physiological conditions |
|
EntK |
Catalytic subunit of bovine enterokinase |
DDDDK‐ |
Serine protease inhibitors, PMSF, imidazole (250 mM), NaCl (250 mM), urea (2 M), SDS |
pH: 6.0‐8.5 Temperature: 4°C‐37°C Activity is highly reduced in phosphate buffers compared to Tris or MES |
Nonspecific proteolysis may occur at secondary sites |
The “–” indicates the site of cleavage within the single letter amino acid code.
See Miyashita et al.,
See Nagai and Thogersen,
Sometimes a protease will fail to cleave the fusion protein. Most often, this is due to steric hindrance in which the protease site is not accessible to the enzyme (Kapust and Waugh,
Several elements of the
BL21Star (DE3) (Invitrogen), a derivative of the BL21 (DE3) strain, contains an additional mutation in the
As described in section II, differences in codon frequency between the target gene and the expression host can lead to translational stalling, premature translation termination, and amino acid mis‐incorporation (Kane,
As discussed in section III, some host strains (BL21 trxB, Origami, Rosetta‐gami) have mutations in thioredoxin reductase (
The BL21‐AI host strain, in which the T7 RNA polymerase gene is under the control of the
As an alternative to the BL21‐AI strain, several BL21 derivatives, known as pLysS strains (also described in section III), express T7 phage lysozyme, an enzyme that effectively inhibits T7 RNA polymerase activity. Inhibition of T7 RNA polymerase, in turn, decreases basal expression of the target protein. Like BL21‐AI strains, pLysS strains have been used to successfully express toxic proteins under the control of T7 RNA polymerase (Jensen et al.,
Typically, protein expression is accomplished using host strains that have a combination of the elements described above. For example, Origami (DE3) pLysS cells have
In
Lowering the expression temperature routinely improves the solubility of recombinantly expressed proteins (Shirano and Shibata,
Because of the profound increase in the yield of soluble protein at low temperatures, it is strongly suggested to use a low induction temperature as the default (see typical protocol in Fig.
In addition to lowering the growth temperature, a reduction in transcription rate can also be achieved by lowering the concentration of the induction agent. For example, the
Although fermentation has its clear advantages, batch culture is the most common method to cultivate cells for recombinant protein expression. Since there is limited control over the growth parameters using this approach, all nutrients that are required for growth must be supplied from the beginning by inclusion in the growth medium. Luria broth (LB) is the standard for the expression of proteins. This broth is composed of bacto‐tryptone, which provides peptides, peptones and essential amino acids, yeast extract, which provides vitamins and trace elements, and sodium chloride, which provides sodium ions to maintain osmotic balance (Sahdev et al.,
Some proteins only express solubly when they are coexpressed with additional biomolecules, typically other proteins, like a binding partner, or molecular chaperones. In these cases, the target protein is coexpressed with a second protein that is encoded on either the same plasmid or a separate plasmid. Multiple vectors have been designed for coexpression of two or more proteins, such as the Duet vectors (Novagen; coexpression of two or more target proteins from the same vector using the T7 promoter system) or separate vectors (Expression Technologies; coexpression of two proteins using two different vectors). Moreover, multiple Duet vectors can be used in the same cell, allowing the expression of up to eight proteins simultaneously. Finally, multiple vectors have been developed that contain
Expressing proteins whose activities disrupt
More recently, these toxin‐antitoxin systems have been used as plasmid‐stabilization systems that can effectively increase recombinant protein production levels. While the antitoxin protein is constitutively expressed from a plasmid that encodes the protein of interest, the toxin gene is chromosomally incorporated and highly repressed in the presence of the antitoxin (StabyExpress, Delphi Genetics). If the plasmid is lost from the host cell, the highly labile antitoxin is readily degraded and the activity of the toxin is no longer inhibited, leading to cell growth arrest. This plasmid‐stabilization strategy, using the CcdA/CcdB toxin‐antitoxin pair, often increases the final recombinant protein production levels by three‐ to five‐fold (Stieber et al.,
Small bacterial proteins typically fold rapidly, due to fast folding kinetics. However, larger bacterial and heterologous proteins fold more slowly, and thus require protein chaperones and folding catalysts to prevent aggregation and facilitate folding in
In our laboratory, we have found that coexpression of protein phosphatase 1 (PP1α), a metal‐dependent serine/threonine phosphatase, with GroEL and GroES results in the maximum yield of soluble protein (Kelker et al.,
All of the parameters listed in this unit, from construct length to inducer concentration, can affect the solubility of recombinant proteins produced in
Flowchart depicting the critical factors to consider, common obstacles, and potential solutions for each stage of protein expression in
The importance of folded, active recombinant protein to the proposed research project defines the amount of time and effort that is devoted to creating the optimal expression protocol. For example, five years were devoted to identifying the optimal expression and purification protocol for protein phosphatase 1 (PP1α) (Kelker et al.,
We thank Dr. Wolfgang Peti for careful reading of the manuscript.